Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 111

Similar articles for PubMed (Select 23356091)

1.

No correlation between plasma NMDA-related glutamatergic amino acid levels and cognitive function in medicated patients with schizophrenia.

Ohnuma T, Sakai Y, Maeshima H, Higa M, Hanzawa R, Kitazawa M, Hotta Y, Katsuta N, Takebayashi Y, Shibata N, Arai H.

Int J Psychiatry Med. 2012;44(1):17-27.

PMID:
23356091
2.

Changes in plasma glycine, L-serine, and D-serine levels in patients with schizophrenia as their clinical symptoms improve: results from the Juntendo University Schizophrenia Projects (JUSP).

Ohnuma T, Sakai Y, Maeshima H, Hatano T, Hanzawa R, Abe S, Kida S, Shibata N, Suzuki T, Arai H.

Prog Neuropsychopharmacol Biol Psychiatry. 2008 Dec 12;32(8):1905-12. doi: 10.1016/j.pnpbp.2008.07.022. Epub 2008 Sep 16.

PMID:
18835577
3.

Prediction of the ability of clozapine to treat negative symptoms from plasma glycine and serine levels in schizophrenia.

Sumiyoshi T, Jin D, Jayathilake K, Lee M, Meltzer HY.

Int J Neuropsychopharmacol. 2005 Sep;8(3):451-5. Epub 2005 Apr 7.

PMID:
15817136
4.

[Could we use a serum level of glycine as a prognostic factor of its efficacy in schizophrenic patients?].

Strzelecki D, Rabe-Jabłońska J.

Psychiatr Pol. 2010 May-Jun;44(3):395-404. Polish.

PMID:
20672518
5.

Plasma glycine and serine levels in schizophrenia compared to normal controls and major depression: relation to negative symptoms.

Sumiyoshi T, Anil AE, Jin D, Jayathilake K, Lee M, Meltzer HY.

Int J Neuropsychopharmacol. 2004 Mar;7(1):1-8. Epub 2004 Jan 13.

PMID:
14720317
6.

Significance of NMDA receptor-related glutamatergic amino acid levels in peripheral blood of patients with schizophrenia.

Ohnuma T, Arai H.

Prog Neuropsychopharmacol Biol Psychiatry. 2011 Jan 15;35(1):29-39. doi: 10.1016/j.pnpbp.2010.08.027. Epub 2010 Sep 7. Review.

PMID:
20828596
7.

Different serine and glycine metabolism in patients with schizophrenia receiving clozapine.

Hons J, Vasatova M, Cermakova E, Doubek P, Libiger J.

J Psychiatr Res. 2012 Jun;46(6):811-8. doi: 10.1016/j.jpsychires.2012.03.015. Epub 2012 Apr 13.

PMID:
22502820
8.

Efficacy of high-dose glycine in the treatment of enduring negative symptoms of schizophrenia.

Heresco-Levy U, Javitt DC, Ermilov M, Mordel C, Silipo G, Lichtenstein M.

Arch Gen Psychiatry. 1999 Jan;56(1):29-36.

PMID:
9892253
9.

Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia.

Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N, Nakazato M, Kumakiri C, Okada S, Hasegawa H, Imai K, Iyo M.

Arch Gen Psychiatry. 2003 Jun;60(6):572-6.

PMID:
12796220
10.

[Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].

Bralet MC, Navarre M, Eskenazi AM, Lucas-Ross M, Falissard B.

Encephale. 2008 Dec;34(6):557-62. doi: 10.1016/j.encep.2007.12.005. Epub 2008 Jul 9. French.

PMID:
19081451
11.

Plasma alanine levels increase in patients with schizophrenia as their clinical symptoms improve-Results from the Juntendo University Schizophrenia Projects (JUSP).

Hatano T, Ohnuma T, Sakai Y, Shibata N, Maeshima H, Hanzawa R, Suzuki T, Arai H.

Psychiatry Res. 2010 May 15;177(1-2):27-31. doi: 10.1016/j.psychres.2010.02.014. Epub 2010 Mar 11.

PMID:
20226539
12.

Relation of plasma glycine, serine, and homocysteine levels to schizophrenia symptoms and medication type.

Neeman G, Blanaru M, Bloch B, Kremer I, Ermilov M, Javitt DC, Heresco-Levy U.

Am J Psychiatry. 2005 Sep;162(9):1738-40.

PMID:
16135636
13.

D-alanine added to antipsychotics for the treatment of schizophrenia.

Tsai GE, Yang P, Chang YC, Chong MY.

Biol Psychiatry. 2006 Feb 1;59(3):230-4. Epub 2005 Sep 9.

PMID:
16154544
14.

The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia.

Vinogradov S, Fisher M, Warm H, Holland C, Kirshner MA, Pollock BG.

Am J Psychiatry. 2009 Sep;166(9):1055-62. doi: 10.1176/appi.ajp.2009.09010017. Epub 2009 Jul 1.

15.

A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia.

Goff DC, Tsai G, Levitt J, Amico E, Manoach D, Schoenfeld DA, Hayden DL, McCarley R, Coyle JT.

Arch Gen Psychiatry. 1999 Jan;56(1):21-7.

PMID:
9892252
16.

D-serine efficacy as add-on pharmacotherapy to risperidone and olanzapine for treatment-refractory schizophrenia.

Heresco-Levy U, Javitt DC, Ebstein R, Vass A, Lichtenberg P, Bar G, Catinari S, Ermilov M.

Biol Psychiatry. 2005 Mar 15;57(6):577-85.

PMID:
15780844
17.

High-dose glycine added to olanzapine and risperidone for the treatment of schizophrenia.

Heresco-Levy U, Ermilov M, Lichtenberg P, Bar G, Javitt DC.

Biol Psychiatry. 2004 Jan 15;55(2):165-71.

PMID:
14732596
18.

A multicenter, add-on randomized controlled trial of low-dose d-serine for negative and cognitive symptoms of schizophrenia.

Weiser M, Heresco-Levy U, Davidson M, Javitt DC, Werbeloff N, Gershon AA, Abramovich Y, Amital D, Doron A, Konas S, Levkovitz Y, Liba D, Teitelbaum A, Mashiach M, Zimmerman Y.

J Clin Psychiatry. 2012 Jun;73(6):e728-34. doi: 10.4088/JCP.11m07031.

PMID:
22795211
19.

High dose D-serine in the treatment of schizophrenia.

Kantrowitz JT, Malhotra AK, Cornblatt B, Silipo G, Balla A, Suckow RF, D'Souza C, Saksa J, Woods SW, Javitt DC.

Schizophr Res. 2010 Aug;121(1-3):125-30. doi: 10.1016/j.schres.2010.05.012. Epub 2010 Jun 11.

20.

Improvement in cognition associated with novel antipsychotic drugs: a direct drug effect or reduction of EPS?

Weiser M, Shneider-Beeri M, Nakash N, Brill N, Bawnik O, Reiss S, Hocherman S, Davidson M.

Schizophr Res. 2000 Dec 15;46(2-3):81-9.

PMID:
11120419
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk